Trevi Therapeutics (TRVI) Starts Key Cough Trials, Is It Still 29% Below Fair Value?
Simply Wall St reports Trevi Therapeutics (TRVI) has started Phase 3 and Phase 2B chronic cough trials and says it has about $188M in cash, cash equivalents and marketable securities at year-end 2025, supporting a runway into 2028. The article cites TRVI shares at $18.50 and a fair value narrative of $26.18.
How this was made
The 30-second read
Why it matters
By stating Phase 3 and Phase 2B trial starts plus an estimated cash runway into 2028, it supports a momentum/bull case. However, it also reiterates that the company remains loss-making and may need further capital, which can cap upside and increase volatility.
Market read
Traders may use the trial-phase kickoff and runway framing to reassess risk, but the article lacks new clinical data or financing specifics that would typically drive a high-conviction trade.
What to watch
No details are provided on trial endpoints, enrollment status, interim read timing, or competitive trial results, which are key drivers of probability-weighted outcomes and dilution risk.
Background
The piece is a Simply Wall St valuation and narrative discussion around Trevi Therapeutics’ chronic cough development and funding position.
Ticker impact
Trevi Therapeutics started Phase 3 and Phase 2B chronic cough trials and cites cash runway into 2028, framing valuation vs fair value.
Near-term trading likely hinges on how investors interpret trial progress versus dilution risk, with valuation premium potentially limiting upside.
The text provides specific trial-phase starts and a cash/runway figure, but it does not include new efficacy/safety results or concrete financing terms, so impact is more narrative than catalyst-driven.
Market effects
Highlights how chronic respiratory pipeline progress and cash runway can drive valuation multiples in small-cap biotech.
No clear regional spillover beyond US small-cap biotech sentiment.
Limited, as the article is company-specific and does not cite global regulatory or competitive actions.
Counterpoint
The valuation discount argument may be overstated because the article emphasizes reliance on a single drug and the possibility of additional capital raising if trial costs extend.
Key entities
- companyTrevi Therapeutics
Subject of the article, with Phase 3 and Phase 2B chronic cough trial starts and a stated cash runway into 2028.
- drug_programHaduvio
The article frames the valuation narrative as built largely around Haduvio and chronic cough programs.
